We serve Chemical Name:N,N-Dimethyl-3-nitropyridin-2-amine CAS:5028-23-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:N,N-Dimethyl-3-nitropyridin-2-amine
CAS.NO:5028-23-9
Synonyms:HOESCRDIWBIVCL-UHFFFAOYSA;2-Pyridinamine,N,N-dimethyl-3-nitro;2-(Dimethylamino)-3-nitropyridine;2-(N-Dimethylamino)-3-nitro-pyridin;2-Dimethylamino-3-nitropyridin;dimethyl-(3-nitro-pyridin-2-yl)-amine;Dimethyl-(3-nitro-[2]pyridyl)-amin;N,N-Dimethyl-3-nitro-2-pyridinamine
Molecular Formula:C7H9N3O2
Molecular Weight:167.16500
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:61.95000
Exact Mass:167.06900
LogP:1.57900
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like HOESCRDIWBIVCL-UHFFFAOYSA chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N-Dimethyl-3-nitro-2-pyridinamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,HOESCRDIWBIVCL-UHFFFAOYSA Use and application,2-Dimethylamino-3-nitropyridin technical grade,usp/ep/jp grade.
Related News: Targets within the tumor microenvironment may include both plasma membrane proteins as well as proteins typically secreted into the extracellular space. N,N-Dimethyl-3-nitropyridin-2-amine manufacturer This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. N,N-Dimethyl-3-nitropyridin-2-amine supplier When they do design their phase 3, they’re going to need to be better about that part of the study design, and really focus on enrolling individuals that have the right biomarkers to be able to look at not only the safety and tolerability but also the efficacy on cognition and function,” Edelmayer said.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. N,N-Dimethyl-3-nitropyridin-2-amine vendor Targets within the tumor microenvironment may include both plasma membrane proteins as well as proteins typically secreted into the extracellular space. N,N-Dimethyl-3-nitropyridin-2-amine factory This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement.
The vaccine approach is promising because using the body’s immune system to fight Alzheimer’s would sidestep one of the problems in developing a drug to treat the disease — namely that it’s difficult to design medications that can easily enter the brain and attack a specific target, Edelmayer explained.
Through booster doses given every three months, the vaccine is “training your body over time how to react to the pathological tau,” Edelmayer said. “You will likely need additional shots of this particular therapeutic to keep it as productive as possible in targeting that tau. N,N-Dimethyl-3-nitropyridin-2-amine vendor Targets within the tumor microenvironment may include both plasma membrane proteins as well as proteins typically secreted into the extracellular space. N,N-Dimethyl-3-nitropyridin-2-amine factory This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement.
